These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11062219)

  • 1. In vitro activity of gatifloxacin against Streptococcus pneumoniae isolates in Germany.
    Reinert RR; Al-Lahham A; Lemmen S; Lütticken R
    J Antimicrob Chemother; 2000 Nov; 46(5):854-6. PubMed ID: 11062219
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.
    Schmitz FJ; Boos M; Mayer S; Hafner D; Jagusch H; Verhoef J; Fluit AC
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2666-7. PubMed ID: 11523528
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
    Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG
    J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
    Boos M; Mayer S; Fischer A; Köhrer K; Scheuring S; Heisig P; Verhoef J; Fluit AC; Schmitz FJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):938-42. PubMed ID: 11181385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal mechanism of gatifloxacin compared with other quinolones.
    Gradelski E; Kolek B; Bonner D; Fung-Tomc J
    J Antimicrob Chemother; 2002 Jan; 49(1):185-8. PubMed ID: 11751786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan.
    Chen JY; Fung CP; Wang CC; Chu ML; Siu LK
    Microb Drug Resist; 2003; 9(2):211-7. PubMed ID: 12820807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.
    Blondeau JM; Zhao X; Hansen G; Drlica K
    Antimicrob Agents Chemother; 2001 Feb; 45(2):433-8. PubMed ID: 11158737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.
    Trampuz A; Laifer G; Wenk M; Rajacic Z; Zimmerli W
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3630-3. PubMed ID: 12384378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.
    Kays MB; Graff MA
    Ann Pharmacother; 2002 Mar; 36(3):416-22. PubMed ID: 11895052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones.
    Reinert RR; Al-Lahham A; Lütticken R; Boos M; Schmitz FJ
    J Antimicrob Chemother; 2002 Jun; 49(6):1015-8. PubMed ID: 12039895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae.
    Schmitz FJ; Fisher A; Boos M; Mayer S; Milatovic D; Fluit AC
    Eur J Clin Microbiol Infect Dis; 2001 Mar; 20(3):219-22. PubMed ID: 11347679
    [No Abstract]   [Full Text] [Related]  

  • 17. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
    Fukuda H; Kishii R; Takei M; Hosaka M
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1649-53. PubMed ID: 11353607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae.
    Klugman K; Wasas A
    J Antimicrob Chemother; 1995 Nov; 36(5):873-4. PubMed ID: 8626270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.